20/20 Biolabs Statistics
Total Valuation
20/20 Biolabs has a market cap or net worth of $2.51 million. The enterprise value is -$1.47 million.
| Market Cap | 2.51M |
| Enterprise Value | -1.47M |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026, after market close.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
20/20 Biolabs has 12.77 million shares outstanding. The number of shares has increased by 47.91% in one year.
| Current Share Class | 12.77M |
| Shares Outstanding | 12.77M |
| Shares Change (YoY) | +47.91% |
| Shares Change (QoQ) | +40.92% |
| Owned by Insiders (%) | 13.24% |
| Owned by Institutions (%) | 6.53% |
| Float | 10.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.23 |
| Forward PS | 1.28 |
| PB Ratio | 1.48 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.99 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.34 |
Financial Efficiency
Return on equity (ROE) is -331.22% and return on invested capital (ROIC) is -112.07%.
| Return on Equity (ROE) | -331.22% |
| Return on Assets (ROA) | -62.37% |
| Return on Invested Capital (ROIC) | -112.07% |
| Return on Capital Employed (ROCE) | -123.20% |
| Weighted Average Cost of Capital (WACC) | 19.36% |
| Revenue Per Employee | $145,729 |
| Profits Per Employee | -$508,216 |
| Employee Count | 14 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 16.18 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -0.43 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 27.83 |
| Average Volume (20 Days) | 229,116 |
Short Selling Information
The latest short interest is 11,270, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 11,270 |
| Short Previous Month | 45,167 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, 20/20 Biolabs had revenue of $2.04 million and -$7.12 million in losses. Loss per share was -$1.00.
| Revenue | 2.04M |
| Gross Profit | 643,094 |
| Operating Income | -4.40M |
| Pretax Income | -5.81M |
| Net Income | -7.12M |
| EBITDA | -4.32M |
| EBIT | -4.40M |
| Loss Per Share | -$1.00 |
Balance Sheet
The company has $4.55 million in cash and $572,448 in debt, with a net cash position of $3.97 million or $0.31 per share.
| Cash & Cash Equivalents | 4.55M |
| Total Debt | 572,448 |
| Net Cash | 3.97M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 3.16M |
| Book Value Per Share | 0.13 |
| Working Capital | 2.52M |
Cash Flow
| Operating Cash Flow | -2.79M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 78,938 |
| Net Borrowing | 1.17M |
| Free Cash Flow | -2.79M |
| FCF Per Share | -$0.22 |
Margins
Gross margin is 31.52%, with operating and profit margins of -215.69% and -285.00%.
| Gross Margin | 31.52% |
| Operating Margin | -215.69% |
| Pretax Margin | -285.00% |
| Profit Margin | -285.00% |
| EBITDA Margin | -211.83% |
| EBIT Margin | -215.69% |
| FCF Margin | n/a |
Dividends & Yields
20/20 Biolabs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.91% |
| Shareholder Yield | -47.91% |
| Earnings Yield | -509.26% |
| FCF Yield | -111.37% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 63.20% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
20/20 Biolabs has an Altman Z-Score of -5.34 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.34 |
| Piotroski F-Score | 3 |